Lux Biosciences Receives Orphan Drug Designation from the FDA for Two...

PR Newswire;  January 15, 2007 ;     700+ words ......PRNewswire/ -- Lux Biosciences, Inc., a privately...next-generation calcineurin inhibitor intended for...of the eye. Lux Biosciences also expects...next-generation calcineurin inhibitor to which Lux...indications that Lux Biosciences will ...

Lux Biosciences Initiates LUMINATE Pivotal Clinical Trials of its...

PR Newswire;  February 20, 2007 ;     700+ words ......PRNewswire/ -- Lux Biosciences, Inc., a privately...next-generation calcineurin inhibitor. The pivotal...quiescent disease. Lux Biosciences is conducting...inhibitor to which Lux Biosciences has an exclusive...is a potent calcineurin inhibitor -- a ...

Lux Biosciences Reports EMEA Acceptance of Its Pediatric Investigation...

Health & Beauty Close-Up;  December 3, 2008 ;     540 words ......for adults. Lux Biosciences completed...next-generation calcineurin inhibitor, voclosporin, to which Lux Biosciences has an exclusive...a potent calcineurin inhibitor (a biological...uveitis, Lux Biosciences is developing...generation calcineurin ...

Isotechnika Signs Agreement Granting Lux Biosciences Worldwide Ophthalmic...

PR Newswire Europe;  May 25, 2006 ;     700+ words ......agreement with Lux Biosciences, Inc. of Jersey...Jersey granting Lux Biosciences worldwide rights...ISA247 is a novel calcineurin inhibitor currently being...agreement: - Lux Biosciences, Inc. will make...million USD. - Lux Biosciences, Inc. will pay...net ...

Isotechnika signs agreement granting Lux Biosciences Worldwide Ophthalmic...

PR Newswire;  May 25, 2006 ;     700+ words ......agreement with Lux Biosciences, Inc. of Jersey...Jersey granting Lux Biosciences worldwide rights...ISA247 is a novel calcineurin inhibitor currently being...agreement: - Lux Biosciences, Inc. will make...million USD. - Lux Biosciences, Inc. will pay...net ...

Lux Biosciences Establishes European-Based Operations.

PR Newswire;  September 18, 2006 ;     621 words ......18 /PRNewswire/ -- Lux Biosciences, Inc., a privately...it has established Lux Biosciences GmbH in Frankfurt...its next generation calcineurin inhibitor, for ophthalmic treatments...executive officer of Lux Biosciences. We strategically...collaborate. About Lux' ...

Lux Biosciences Announces Exclusive Worldwide License Agreement with NIH...

PR Newswire;  November 7, 2006 ;     700+ words ......Stage Program in the Lux Biosciences Pipeline and Will...PRNewswire/ -- Lux Biosciences, Inc., a privately...significant milestone for Lux in our first year...next generation calcineurin inhibitor for the treatment...Executive Officer of Lux Biosciences. We ...

Orphan status given to two drugs

Ophthalmology Times;  February 15, 2007 ;     140 words ......designation to two investigational therapeutics of Lux Biosciences, a privately held biotechnical company specializing...The designation was given to LX211, a next-generation calcineurin inhibitor intended for the treatment of noninfectious posterior...the company is first to receive marketing ...

Isotechnika's Lead Immunosuppressive Drug, ISA247 Positioned to Enter...

PR Newswire Europe;  November 28, 2006 ;     700+ words ......by its partner Lux Biosciences, following interactions...agreement with Lux Biosciences, Inc. of Jersey...Jersey granting Lux Biosciences exclusive, worldwide...gov or contact Lux Biosciences for further information...President & CEO of Lux ...

Isotechnika's lead immunosuppressive drug, ISA247 positioned to enter...

PR Newswire;  November 28, 2006 ;     700+ words ......by its partner Lux Biosciences, following interactions...agreement with Lux Biosciences, Inc. of Jersey...Jersey granting Lux Biosciences exclusive, worldwide...gov/ or contact Lux Biosciences for further information...President & CEO of Lux ...

Lux Biosciences to Present at RBC Capital Markets Healthcare Conference.

PR Newswire;  December 7, 2006 ;     414 words ......7 /PRNewswire/ -- Lux Biosciences, Inc., a privately...presentation. About Lux Biosciences Lux Biosciences is a privately held...including a next-generation calcineurin inhibitor that has potential...More information on Lux Biosciences can be found at ...

Isotechnika Inc. announces highlights and financial results for second...

PR Newswire;  August 3, 2006 ;     700+ words ......Isotechnika signed an agreement with Lux Biosciences, Inc. of Jersey City, New Jersey on May 24, 2006, granting Lux Biosciences, Inc. the worldwide rights to...the terms of the agreement: - Lux Biosciences, Inc. will make upfront and...

EMEA Committee Recommends Orphan Medicinal Product Designation for ISA247...

PR Newswire Europe;  August 1, 2007 ;     700+ words ......Isotechnika's partner, Lux Biosciences, began enrolling patients...lead drug, ISA247, is a calcineurin inhibitor to which Lux Biosciences has an exclusive worldwide...addition to uveitis, Lux Biosciences plans to develop this...macular degeneration. Lux ...

Isotechnika's partner, Lux Biosciences, receives no objection letter from...

PR Newswire;  May 2, 2007 ;     700+ words ......today announced that its partner, Lux Biosciences, has received a No Objection Letter...trials for the treatment of uveitis. Lux Biosciences commenced patient treatment in its...graft rejection. One of our partners, Lux Biosciences, has received permission from the...

Two ophthalmic products gain orphan drug status.(RESEARCH ALERT)

Biomedical Materials;  March 1, 2007 ;     319 words ......Administration (FDA) for their developer Lux Biosciences Inc. Orphan drug designation...minimally invasive procedure. Lux will clinically evaluate the...in corneal transplantation. Lux Biosciences was previously granted orphan...LX211, is a next-generation calcineurin ...